Abstract Background and Aim Sodium valproate (SV), a novel class of histone deacetylases
(HDACs) inhibitors commonly used as an antiepileptic drug. HDAC inhibitors are known to …

Sodium valproate (VPA) has been recently identified as a selective class I histone
deacetylase (HDAC) inhibitor and explored for its potential as an anti‐cancer agent. The anti …

Background Colorectal cancer (CRC) is one of the frequently diagnosed cancers worldwide.
Currently used chemotherapeutic drugs have several side effects. Histone deacetylase …

Unbalanced histone deacetylase (HDAC) hyperactivity is a common feature of tumor cells.
Inhibition of HDAC activity is often associated with cancer cell growth impairment and death …

Background/Aims: Histone deacetylases (HDACs) modulate lysine acetylation on histones
and are frequently deregulated in cancer. HDAC inhibitors with potent anti-tumour effects …

Valproic acid (VPA) as a histone deacetylase (HDAC) inhibitor has an anticancer effect. In
the present study, we evaluated the effects of VPA on the growth and death of HeLa cervical …

The level of histone deacetylation is closely associated with the genesis and development of
tumors, but the antitumor effect and mechanism of the class I histone deacetylase inhibitor …

Histone deacetylase inhibitors (HDACIs) are novel anticancer agents with potent cytotoxicity
against a wide range of malignancies. We have previously demonstrated that either …

Histone deacetylase inhibitors (HDACIs) are a promising class of drugs that act as
antiproliferative agents by promoting differentiation and inducing apoptosis. Valproic acid …

Histone deacetylase is strongly associated with epigenetic regulation and carcinogenesis,
and its inhibitors can induce cell cycle arrest and apoptosis of the cancer cells. In this study …